^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Vimo (alpha-tocopheroloxyacetic acid)
i
Other names: α-TEA, alpha-TEA, VT101, VT-101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Veana Therap
Drug class:
Apoptosis stimulant, Immunostimulant, Immunomodulator
Related drugs:
4ms
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=24, Suspended, Veana Therapeutics | Trial completion date: Feb 2025 --> Feb 2030 | Recruiting --> Suspended | Trial primary completion date: Feb 2024 --> Feb 2028
Trial completion date • Trial suspension • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Vimo (alpha-tocopheroloxyacetic acid)
over2years
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer (clinicaltrials.gov)
P1; Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2024
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CCR7 (Chemokine (C-C motif) receptor 7) • LAMP1 (Lysosomal Associated Membrane Protein 1) • LAMP2 (Lysosomal Associated Membrane Protein 2)
|
HER-2 positive • HER-2 overexpression
|
Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Vimo (alpha-tocopheroloxyacetic acid)
Share via
